Autolus Therapeutics announces publication in Blood Cancer Journal
Morning Star,
LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company…
LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company…
LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company…
LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company…
LONDON, March 11, 2024 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-genera…
LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc AUTL, a clinical-stage biopharmaceutical company developing…
LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company…
LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company…
LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company…
LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company…
LONDON, Feb. 22, 2024 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generat…
LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company…
The CAR T-cell therapy AUTO4 was not associated with dose-limiting toxicities (DLTs) and led to early indications of efficacy…
1. The β-chain constant region of the T cell receptor (TCR) was targeted to specifically eliminate a population of malignant T…
A novel method discovered can target the abnormal T-cells without destroying healthy T-cells and can lead to new treatment for…
A unique approach to targeting the abnormal T-cells that cause T-cell lymphomas could offer hope to patients with the…
A unique approach to targeting the abnormal T-cells that cause T-cell lymphomas could offer hope to patients with the…
The team of researchers, working with biopharmaceutical company Autolus Ltd, have discovered a method of targeting the cancer…
A unique approach to targeting the abnormal T-cells that cause T-cell lymphomas could offer hope to patients with the…
A new study from Cardiff University reveals a unique approach to targeting the abnormal T-cells that cause T-cell lymphomas and…
A unique approach to targeting the abnormal T-cells that cause T-cell lymphomas could offer hope to patients with the…
A unique approach to targeting the abnormal T-cells that cause T-cell lymphomas could offer hope to patients with the…
A unique approach to targeting the abnormal T-cells that cause T-cell lymphomas could offer hope to patients with the…
A Nature Medicine study published Monday describes a chimeric antigen receptor (CAR)-based strategy to target T cell…
A Nature Medicine study published Monday describes a chimeric antigen receptor (CAR)-based strategy to target T cell…